Peptide-Based Dry Eye Composition for Tear Volume and Corneal Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current dry eye therapies, such as those using viscoelastic compounds like methyl cellulose and hyaluronic acid, are ineffective in addressing the pathological changes in corneal epithelial cells and tear film imbalances, leading to reduced tear volume, corneal surface irregularities, and inflammation.
Innovation Solution
A pharmaceutical composition containing a novel peptide with specific amino acid sequences (GDRGD and GQDGLAGPK) is used to improve tear production, reduce corneal epithelial cell detachment, and suppress inflammatory factors, derived from collagen type I α1 and II α1, respectively, isolated from animal-derived chondrocyte extracellular matrices.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If viscoelastic compounds such as methyl cellulose, chondroitin sulfate, and hyaluronic acid are used as substitutes for mucin in artificial tears, then the therapy can be applied to dry eye treatment, but the efficacy is limited because these compounds are physically and physiologically different from mucin
Solution Approach 1:
The invention changes the chemical structure parameter of the artificial tear composition by incorporating specific peptides (GDRGD and GQDGLAGPK) that mimic the physiological properties of natural mucin, thereby improving both efficacy and physiological compatibility
Solution Approach 2:
The invention creates a composite material system combining multiple peptides with specific amino acid sequences that work synergistically to replicate the complex functional properties of natural mucin, achieving superior therapeutic效果 compared to single-component viscoelastic compounds
2Quantity of substance
If conventional artificial tears are used to treat dry eye, then tear film substitution is provided, but they fail to address pathological changes in corneal epithelial cells and tear film imbalances
Solution Approach 1:
The peptide-containing composition performs multiple functions simultaneously: it supplements tear volume like traditional artificial tears while also promoting corneal epithelial cell regeneration and reducing inflammation, thereby addressing both symptomatic and pathological aspects of dry eye disease
Data Source
AI summary
The present invention relates to a pharmaceutical composition for preventing or treating dry eye, the pharmaceutical composition including, as an active component, a novel peptide is disclosed, wherein it is confirmed that the peptide has effects on improving tear production and corneal surface smoothness for dry eyes induced by desiccation stress and suppressing detachment of corneal epithelial cells, reduction in conjunctival goblet cells, and generation of inflammatory factors, thereby applying a composition including the peptide as an active component to the pharmaceutical composition for preventing or treating dry eye.